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Objectives . A new percutaneous collagen hemostasis device was
compared with conventional compression techniques after ding-
nostic catheleriTation and angioplasty .
Background. Peripheral vascular compficationsafter diagnos-
tic catheterization or more complex hilerventional procedures, as
well as the discomfort of manual compression and prolonged hed
rest, represent significant morbidity for invasive cardiac proce-
dures .
Methods. A prospective, multicenter, randomized trial was
designed to compare the hemostasis time in minutes and the
incidence of vascular complications in patients receiving a vascu-
lar hemostasis device with those undergoing conventional com-
pression techniques.
Results. After diagnostic catheterization, hemoslasis time was
significantly less with the vascular hemostasis device than with
conventional manual compression (4 .  ± 2.8 min [n =: 9  patients]
vs .  7.6 ± 9.2 min In = 75 , p <   .    ) . This difference was
greater in patients undergoing angioplasty and was unrelated to
the anticoagulation status (4.3 ± 3.7 min In = 7  not receiving
heparin], 7 .6 ±   .6 min In = 85 receiving heparin], 33 .6 ±
24.2 min In =  34 control patients not receiving heparin], p <
 .     vs . control patients) . The time from the start of the
procedure to ambulation was slightly less after diagnostic cathe-
Peripheral vascular complications after diagnostic catheter-
ization or more complex interventional procedures ( -9), as
well as the discomfort of manual compression and prolonged
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ferization in patients treated
with
the device ( 3.3 ±  2.  h vs .
 9.2 ±  7.3 it, p <  . 5) . It was also less in patients who
underwent angioplasty when the device was used after discontin-
uation of anticoagulation (23.  ±   .  h, without heparin), as
compared with control compression techniques (32,7  &8 It,
p <  .    ) . Time to ambulation was even shorter ( 6 .     .  h,
p <  .   ) in patients in whom the device was placed immedi-
ately after angioplasty while they were still folly anticoagulated
with a prolonged activated clotting time (336 t 85 s). There were
no major complications (surgery or transfusion) after diagnostic
catheterization ants a low incidence of major complications in
patients who underwent angioplasty (  .7% in control patients,
IA% with the device without heparin,   % with the device and
heparin, p = NS) . After angioplasty, there was a trend toward
fewer hematomas when the device was used in the absence of
heparin (4 .2% vs. 9 .7% in control patients, p =   . 4) .
Conclusions . A new vascular hemeFtasis device can signifi-
cantly reduce the puncture site hentosiasis tine and the time to
ambulation without significantly increasing the risk of peripheral
vascular complications. The role of this technology in reducing
complications, length of hospital stay and cost remains to be
determined .
(J Am CNN CArdW  993,22: 273
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bcd rest, represent significant morbidity for invasive cardiac
procedures . Complications requiring vascular surgical repair
range from  .5% after diagnostic catheterization (2) and  %
to 2% after conventional balloon angioplasty (3-5) up to 3%
after atherectomy (8) and I % after coronary stem place-
ment (`V' because of the use of a larger sheath size and the
need for greater anticoagulation . The requirement for large
doses of heparin during and immediately after angioplasty
also delays sheath removal, which, in turn, requires more
intensive nursing care and prolongs hospital stay
. Thus, a
technique that could rapidly seal the arterial puncture site
despite full anticoagulation and permit earlier ambulation
without increasing complications could have a significant
impact on the practice of invasive cardiology .
Recently, a novel vascular hemostasis device was devel-
oped that delivers purified, absorbable bovine collagen
 735-  97/93/56 .  
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through an introducer sheath to promote hemostasis at the
arterial puncture site (VasoSeal Datascope) . Although initial
preclinical (  ) and clinical (  - 3) evaluations indicate the
safety and efficacy of this device, controlled clinical trials
have not been reported
. In the present study, a randomized,
multicenter trial was performed to evaluate this device in
comparison with conventional compression techniques for
obtaining hemostasis at the arterial puncture site after diag-
nostic catheterization and angioplasty .
Methods
Study design . A prospective, multicenter, randomized
trial was designed to compare the hemostasis time in minutes
and the incidence of vascular complications in patients
receiving a vascular hemostasis device with those undergo-
ing conventional compression techniques in three progres-
sive phases :  ) patients undergoing diagnostic catheteriza .
tion ; 2) patients undergoing angioplasty in whom sheaths
were removed, is is customary after discontinuation of
heparin ; and 3) patients undergoing angioplasty in whom the
vascular hemostasis device was applied immediately after
angioplasty while they still had full anticoagulation . Because
a control study for phase 3 of immediate sheath removal
while patients still had full anticoagulation would cause
significant bleeding and be unethical, the control group for
phase 3 was conventional compression after discontinuation
of anticoagulation, as in phase 2 . These control groups were
then combined in the analysis, Retrospectively, the time to
ambulation in hours was also calculated and compared
between treated and control patients .
Patient enrollment . Our study included patients undergo •
ing diagnostic cardiac catheterization or balloon angioplasty
who were >2  years old, had the ability to give written
consent and understood the obligation for follow-up study .
Patients were excluded if they were markedly obese, had
known platelet dysfunction, had uncontrolled hypertension
or had a hematoma during the catheterization or angioplasty
procedure . Patients undergoing atherectomy or intracoroy
nary stem placement were not enrolled in this trial because
these interventions required either larger sheaths or greater
anticoagulant regimens . They will be the subject of future
randomized trials. The protocol was approved by the Insti-
tutional Review Board of the first participating medical
center on September  6,  99  .
Physician training. Two investigators (T .A.S., G .S.R .)
had preclinical experience with this device in normal swine
femoral arteries. One investigator (T.A.S .) had experience
with this device in 2  patients during a pilot stage (phase  )
clinical evaluation (  ). The other three investigators started
this randomized clinical trial after observing the vascular
hemostasis device being placed by one of the earlier inves-
tigators in one to two patients . Thus, the present randomized
trial represents the initial clinical experience with this device
for the majority of the investigators .
I
Figure   . The vascular hemostasis device consists of an    .5F
sheath of variable length . Sheaths of all seven lengths are shown
(top), one blunt    7 dilator (middle row, right), a short  . 35-in .
(  . 89-cm) guide wire (bottom) and two collagen-filled cartridges
(middle row, left) .
Vascular hemostasis device and technique . The vascular
hemostasis device used in this trial consisted of four parts
(Fig.  ) : a blunt-tipped I IF dilator, one of seven difi"erently
sized    .5F sheaths selected by length using a preprocedure
needle depth measurement technique and two 9 -mg colla-
gen cartridges .
At the beginning of each cardiac catheterization or angio-
plasty, the distance between the femoral artery and the skin
was measured . After the artery was punctured with a single
entry needle and a conventional  . 35-in. ( . 89-cm) guide
wire was inserted through the needle loco the artery, a clip
was placed on the needle where it entered the skin while
maintaining arterial compression (Fig . 2). The needle with
the clip intact was then removed and a 4F to 9F sheath was
inserted over the guide wire to begin the procedure . The
distance between the clip and the tip of the needle was then
measured to select which of seven differently sized    .5F
sheath kits of slightly shorter lengths should be used at the
time of sheath removal .
When the sheath was to be removed, the following
sequence was employed (Fig . 3) :
 ) A short  . 35-in. guide wire was inserted, and the
existing sheath was removed while hemostasis was main-
tained with manual compression . Then, a blunt-tipped I I F
dilator was inserted over the guide wire down to the arterial
puncture site using a combination of tactile feedback to feel
the resistance of the dilator against the outer surface of the
Figure 2 . Drawing showing the method of measuring the skin to
artery distance . A clip is placed on the single entry needle while
arterial compression is maintained by hand .
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Figure 3. A, The   
.5 7 dilator and sheath system is advanced over
a guide wire to the surface of the femoral artery
. B, During complete
manual arterial compression, the guide wire and dilator are re-
moved, and collagen is advanced through the sheath into the track
from the femoral -rtery to the skin . C, Hemostasis is completed
after a short perieir f manual compression
.
artery and a marker on the dilator to confirm the previously
measured skin to artery distance . The    .5F applicator
sheath, selected by length, was then advanced over the
dilator down to the arterial surface .
2) While arterial compression was maintained, the dilator
and guide wire were removed, and the first collagen cartridge
was advanced, as with an injection, out of the sheath while
the sheath was slowly pulled back, to fill the track through
the subcutaneous tissue . The second collagen cartridge was
then applied while the sheath was gradually pulled back to
completely fill the track up to the skin surface .
If one
cartridge of collagen completely filled the subcutaneous
track, as in a thin person, a second collagen cartridge was
not required .
3) After the collagen cartridges were applied, the    .5F
applicator sheath was removed completely and partial up-
stream compression, as well as light pressure directly over
the dermotomy, was applied for 2 to 5 min to obtain
complete hemostasis . To decrease the possibility of infec-
tion, care was taken to ensure that no collagen protruded
SANBORN ET AL .
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above the skin suoare. Small amounts of protruding colla-
gen could be pressed under the skin surface by using the
blunt-tipped dilator . If a significant segment of collagen did
protrude above the skin, it could easily be cut with sterile
scissors . thereby avoiding much manipulation and pushing
of the collagen .
Conventional compression techniques . In control patients,
the sheath was removed and hemostasis was obtained with
conventional manual compression . In some institutions, it
was customary to use mechanical C clamps to aid in the
hemostasis procedure after angioplasty because hemostasis
took longer in patients undergoing angioplasty . These prac-
tices were not altered for this protocol .
Heparinization . For diagnostic catheterization, heparin
was not routinely given in the majority (79%) of patients . In
2 % of both control and treated patients (p
4
NS), a small
amount of heparin ( ,    to 2,5   U was given during the
study). In patients undergoing angioplasty,   ,    to
2 ,    U of heparin was given intravenously during the
procedure, with systemic anticoagulation maintained over-
night and then discontinued before sheath removal . As
mentioned previously in phase 3, in patients treated with the
vascular hemostasis device, the sheath was pulled in the
catheterization laboratory while they were still had full
anticoagulation as documented by prolonged activated clot-
ting time . Systemic anticoagulation was continued over-
night, as in control patients undergoing angioplasty, unless a
large (>6-cm) hematoma developed .
Definitions . The following definitions or descriptions of
techniques were used in this study :
 ) The hemostasis time for all groups was defined as the
time elapsed from initial compression and removal of the
preexisting sheath until the completion of compression . For
control patients, compression had to be maintained for a
minimum of    min after diagnostic catheterization and
 5 min after angioplasty before the puncture site could be
inspected to determine whether hemostasis was complete
and bleeding or swelling was absent . From prior preclinical
(  ) and clinical studies (  - 3) with the vascular hemostasis
device, it was determined that the puncture site could be
inspected for completion of compression in only   to 2 min .
In all patients, a schedule was developed for additional
compression based on the extent of bleeding . A small
amount of bleeding (oozing) was treated with an additional
2 to 5 min of manual compression, whereas brisk bleeding
(spurting) was treated with an additional 5 to
   min of
compression
. This sequence of inspection and compression
was continued until hemostasis was achieved
and the
elapsed time recorded . After hemostasis was achieved, an
adhesive bandage or light pressure dressing was applied to
the puncture site in all patients .
2) Ambulation time
was calculated as the total time from
start of the procedure until ambulation
(i .e ., total duration of
bed rest) .
3) Peripheral vascular complications were categorized as
follows
: a) those requiring vascular surgical repair for bleed-
 2?b
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Table   . Patient Demographics
ing, large pseudoaneurysm, arteriovenous fistula, thrombo-
sis or loss of distal pulse ; b) transfusion due to bleeding at
the puncture site ; c) deep vein thrombosis ; d) infection at the
puncture site requiring intravenous antibiotics ; c) bleeding
from the puncture site ; f) small pseudoaneurysms treated
medically; and g) hematomas (2 to 6 cm and >6 cm).
Follow-up. Clinical follow-up was obtained daily while
patients w',re in the hospital, as well as at 3 and 3  days after
sheath removal . The puncture site was inspected for evi-
dence of arteriovenous fistula, pseudoaneurysm formation,
loss of distal pulse, emboli, swelling, hematoma, bruising,
itching or redness. If a pseudoaneurysm was suspected, it
was confirmed and documented by ultrasonography regard-
less of size and requirement for surgical repair .
Statistics, Results obtained with the vascular hemostasis
device and conventional compression were compared using
nonpaired r test analysis for patients undergoing diagnostic
catheterization and one-way analysis of variance for patients
undergoing angioplasty. A p value <  . 5 was considered
significant,
Resorts
Patient enrllment . Between September 23,  99  and
February 28,  992, 455 patients were enrolled in this study ;
246 were randomized to treatment with a vascular hemosta-
sis device and 2 9 to control compression techniques . The
hemostasis device could be successfully placed in 24  (98%)
of 246 attempts . The five device failures were related to
kinking or accidental removal of the    .5F sheath from the
track through the subcutaneous tissue, These patients were
treated with conventional manual compression without com-
plications . Their data were still included in the study on the
basis of intention to treat with the vascular hemostasis
device.
Patient . The clinical characteristics, rele-
vant preprocedure laboratory data and specific procedural
data for each group are summarized in Tables   and 2
. There
were no major differences in these baseline characteristics
JACC Vol. 22, No . 5
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Values presented are mean value ± SD or number (%'n) of patients, BP
-
blood pressure : Pts - patients ; VHD = vascular hemostasis device .
beta ,• patients treated with the vascular hemostasis de-
vice and the control patients . In patients undergoing angio-
plasty, the preprocedure partial thromboplastin time was
higher in the group randomized to receive the vascular
hemostasis device in the absence of heparin (p <   . 5 vs .
control) . Although this difference was statistically signifi-
cant, it was not relevant at the time of sheath removal .
Sheath size distribution was also similar between groups,
although slightly more 8F sheaths were used in the patients
in the angioplasty group who received the device in the
absence of heparin than in the control group .
hemostasis time. In patients undergoing diagnostic cath-
eterization, the time to hemostasis time was significantly
shorter with the vascular hemostasis device than with con-
ventional manual compression (4 .  ± 2.8 min [n = 9 
patients] vs .  7.6 ± 9.2 min In = 75 , p <   .     [Table 3]) .
This decrease was even more striking in patients undergoing
angioplasty (4 .3 ± 3.7 min [n = 7 , device given in the
absence of heparin] vs . 33.6 ± 24.2 min in =  34 in the
control group], p <  .     vs. control patients [Table 3]) .
Among patients receiving the vascular hemostasis device,
there was no significant difference between the hemostasis
time of those undergoing diagnostic catheterization or angio-
plasty. Furthermore, a reduced hemoslasis time could also
be achieved when the angioplasty sheaths were pulled while
the patients still had full anticoagulation (7 .6 ±    .6 min [n =
85 receiving heparin], p <   .    ) .
Ambulation time. Although it was not specifically ad-
dressed in this trial, the vascular hemostasis device also had
an impact on the time to ambulation after diagnostic cathe-
terization and angioplasty . In phase I of this study (diagnos-
tic catheterization), the majority of investigators were pri-
marily concerned with learning how to perform this
hemostasis technique and avoid complications . Therefore,
early ambulation after use of the vascular hemostasis device
was not pursued. However, the time from the procedure to
ambulation was slightly lower in those patients treated with
the hemostasis device (.3.3 ±  2 .  h vs,  9.2 ±  7.8 h, p <
 . 5 [Table 3]). In the angioplasty group there were more
Coronary Angioplasty
Diagnostic Catheterization VHD
Control GrouI
VHD Control Group
Without Heparin With Heparin
Pts
75 9 
 34 7 85
Age (yr)
62 .8 ±    .7 62
.4 ±    .8 6  .3 ±    .  58
.6 ± 9
.8
6  .8 ± 9.8
Men
54(72)
64(72) 87(65)
52(73) 65(76)
Women
2 (28) 2 28)
47 (35)  9(27) 2 (24)
Height (cm)  73.3 ± 9.7
 74.  ±   .3  73.  ± 9 .5  75,4 ±  3 .9  74 .9 ±   . 
Weight (kg)
79 .  ±  2 .2
8  .4 ±  6 .8
8  .4 ±  3.2 8  .8 ±  6 .5 8  .  ±  5 .2
Systolic liP (mm Hg)
 32 t  9  35 ± 2 
 26 ±  7  26 ±  7  3  .  * 22.6
Dmbetes
9( 2)  6 8)
26( 9   4(2 )
 4( 7)
Prior puncture (same side)
25 3) 28 2)
79(59)
3  (45  49 8)
Oral saliaylates
39(52)
49 4)  34 (   )
7  (   ) 85   )
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Table 2. Baseline Laboratory Data and Procedural Sheath Size
*p <   . 5 versus control group . Values presented are mean value ± SD or number of p atients . P T = pio!hrombin time ; li'T = partial thromboplastin
time, other abbreviations as in Table  ,
significant differences in the ambulation times even though
the early ambulation was not a specific goal of this initial
study. For example, the time from the start of the procedure
to ambulation or total duration of bed rest was significantly
less when the vascular hemostasis device was used after
discontinuation of anticoagulation (23 .  ±    .  h) as com-
pared with the control time with compression techniques
(32.7 ±  8.8 h, p <  .    ). An even shorter time to
ambulation ( 6.  ±   .  h, p <   .    ) was noted in those
patients in whom the device was placed immediately after
angioplasty while they still had anticoagulation with a pro-
longed activated clotting time (336 ± 85 s) .
Peripheral vascular complications . In this medium-sized
trial, the overall incidence of peripheral vascular complica-
tions was quite low (Table 4) . There were no major compli-
cations after diagnostic catheterization and a low incidence
of major complications after angioplasty . For example,
bleeding requiring a transfusion was observed in one control
angioplasty group patient in the (  .7% incidence) and one
patient in whom the hemostasis device was placed immedi-
ately after angioplasty (  .2% incidence) . In addition, in the
group in which the hemostasis device was placed after
discontinuation of heparin, there was one case in which a
nonischemic, diminished, but detectable, distal pulse was
noted after use of the device (  .4% incidence) . Nonemergent
Table 3. Times to Hemostasis and Ambulation
Diagnostic Catheterization
Control Group VHD
local exploration revealed a portion of the collagen protrud-
ing into the lumen of the common femoral artery. The
collagen was removed, no thrombosis or embolus was de-
tected, the arteriotomy was closed with sutures and a good
distal pulse was restored . The incidence of these major
complications was not significantly different .
The incidence of minor complications was also similar
and not significantly different between groups (Table 4) . All
pseudoaneurysms could be treated conservatively with med-
ical management and full resolution documented on follow-up
ultrasound Study . Although there were no significant differ-
ences in the incidence of hematoma formation in patients
undergoing diagnostic catheterization, there was a trend to-
ward a lower incidence of hematomas in patients in the
angioplasty group who had the vascular hemostasis device
placed while not being treated with heparin (4 .2% vs . 9 .7% in
the control group, p =  . 4). Furthermore, there was no
significant increase in the incidence of hematomas in patients
whose vascular hemostasis device was placed while they still
had full anticoagulation .
Occasionally hemostasis could not be obtained with this
device more rapidly than with control manual compression .
Most likely this was due to accidental delivery of collagen
along one side of the artery or sliding of the material
proximal to the arteriotomy during the insertion procedure,
Control Group
Coronary Angioplasty
Without Heparin
VHD
With Heparin
*p <  .     versus control group . tp <   . 5 versus control group . Values presented are mean value ± SD or number
. Abbreviations as in Table I -
Pts 75 9   34
7  85
Hemostasis time (min)  7 .6 ± 9 .2 4 .  ± 2 .8* 33 .6 ± 24 .2 4 .3 ± 3 .7*
7 .6 ±    .6
Ambulation time (h)  9 .2 ±  7 .8  3 .3 ±  2 . t 32 .7 ±  8 .8 23 .  ±    . *
 6 .  ±    .  ,
Coronary Angioplasty
Diagnostic Catheterization
VHD
Control Group VHD Control Group Without Heparin With Heparin
Pts 75 9   34 7 
85
Laboratory data
Hematocrit 4 .8±6.7 4 .7 ±5 .i 4 . ±4.8
4 .5±4 .539.6±6.8
PT (s)  2.2± .4  2.5±5.6  2.2± .3
 3 ±  3
ul ± Is
PTT (s) 33.  ±    .5 35 .6 ±  3 8 37 .9  8 .2 52 .9 ± 5  .9* 36 .2 ±  6.9
Platelet count (x    3/mm -  ) 256 ± 8  248 ± 78 25) 79 263 ± 84 247 ± 79
Sheath size
6F  2( 6)  7( 9) 2(2)
2 (2)  
7F 36(48) 39(43)   (8)   ( ) 3(4)
8F 27 (36) 33(37)   7 (87) 7  (99)* 78 (92)
9F 4(3)  ( ) 2 (2)
Unknown   ( )  (I)
 278
	
SANBORN ET AL
.
PERCUTANEOUS COLLAGEN HEMOSTASIS DEVICE
Table 4. Peripheral Vascular Complications
as observed in experimental animal studies (  ) . More recent
in vitro and experimental animal studies with an over the
wire collagen delivery system indicate that this malalignment
can be reduced . Whether other materials will turn out to be
more effective than collagen in obtaining rapid hemostasis
without complication remains to be determined . Four pa-
tients underwent emergency angioplasty for abrupt closure
using either the ipsilateral or contralateral femoral artery
within hours or days of collagen sealing without complica-
tions . However, this issue needs further investigation in a
larger number of patients .
Discussion
lift this multicenter randomized trial, a new vascular
hemostasis device was found to significantly reduce both
puncture site compression or hemostasis time, and the time
to ambulation after diagnostic catheterization and angio-
plasty without increasing peripheral vascular complications
from those obtained with conventional manual compression .
The device itself has a relatively simple percutaneous design
and uses purified degradable bovine collagen that has previ-
ously been approved by the Food and Drug Administration
for use in vascular surgical repair. The trial is unique in that
it was initiated with the initial clinical experience of the
majority of investigators. Thus, it represents the very early
experience with this device .
   lemahtsis time. The most striking clinical observations
with this percutaneous collagen device were the ability to
rapidly seal the arterial puncture site in just a few minutes
and the associated reduction in compression time . The time
to hemostasis was significantly reduced after diagnostic
catheterization and angioplasty to values approximately 5 to
*p a   . 4 versus control group . Values presented are number (%) . DVT = deep vein thrombosis ; other abbreviations as in Table   .
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8 times less than those observed in comparable patients
treated with conventional manual compression, as reported
in this series and in previous studies ( 4, 5) . The hemostasis
time could be significantly reduced regardless of aspirin
administration or systemic anticoagulation, an effect due to
the inherent hemostatic properties of collagen, which are
reported to operate irrespective of heparin ( 6) .
Ambulation time, In this study early ambulation was not
specifically pursued and, for the most part, standard post-
angiography or angioplasty protocols were followed at each
particular institution . However, as investigators became
experienced and comfortable with this collagen device,
ambulation was initiated earlier after the procedure, partic-
ularly in patients whose sheath was removed immediately
after angioplasty. Early ambulation 2 to 3 h after diagnostic
catheterization with SF angiographic catheters has already
been reported with conventional manual compression ( 7) .
Whether ambulation within V2 to I h of the procedure is
realistic, safe and effective, as was occasionally observed
with this device, remains to be examined . Obviously, if
patients are hemodynamically unstable and require arterial
pressure monitoring, it may not be appropriate to use a
hemostasis device to remove a sheath early .
Peripheral vascular complications. Currently there are no
standard classifications or categories of peripheral vascular
complications after diagnostic catheterization or angio-
plasty. In previous studies, peripheral vascular complica-
tions are often defined only as those requiring vascular
surgical repair ( ,2) . Other studies (4-9) have reported
complications, such as bleeding requiring transfusion, infec-
tions, pseudoaneurysms, arteriovenous fistulas, thrombosis,
embolization and hematomas . Therefore, in the present study,
complications were arbitrarily analyzed, as in Table 4 .
Diagnostic Catheterization
Coronary Angioplasty
Control Group
VHD
Control Group
VHD
Without Heparin With Heparin
Pts
75 9 
 34 7  85
Major Complications
Surgical repair
 
 
   
Transfusion
   
   
Total
   
 (  .7)  
( 
A)   (  
Minor complications
DVVT
     
Infection
 
 
 
ding
 
   
Pseudoaneurysm
  2
Total
2(2 2)
4(3 . ) I ( A) 6(7 . )
Hematomas
2 to 6 cm 4
4 9 2 4
>6 cm
  3 4   7
Total
4(5 .3) 7 (7 .8)  3 (9 .7)  2 4. 
JACC Vol . 22, No . 5
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Overall, the incidence of all these complications was low in
both control and treated patients .
Study limitations . With this low incidence of complica-
tions, the number of patients in this study was too small to
draw any conclusions as to whether this collagen hemostasis
device can reduce peripheral vascular cornplical;ons associ-
ated with cardiac catheterization and angioplasty . This study
also represents an early experience affected by both an
operator learning curve and the developmental stages of a
new device . Investigators have now been instructed to
advance the collagen less forcefully (nee contact has been
made with the arteriotomy . Additional device modifications
currently under evaluation in the experimental laboratory
should also improve the safety and efficacy of this device,
Conclusions . A new vascular hemostasis device evalu-
ated in a multicenter randomized trial as part of an initial
investigational device exemption from the Food and Drug
Administration was found to significantly reduce both the
puncture site time to hemostasis and the time to ambulation
without significantly increasing the risk of peripheral vascu-
lar complications . There was a suggestion that it may de-
crease hematoma formation after coronary angioplasty in
patients not receiving heparin. Furthermore, this device
permitted the safe removal of angioplasty sheaths in patients
with full anticoagulation . This effect may prove useful when
prolonged anticoagulation is desired or necessary, as with
- placement of intracoronary stents . The role of this
technology in reducing peripheral vascular complications,
length of hospital stay and costs remain to be determined .
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